Skip to main content
Home > BioCentury on BioBusiness > Product R&D

Chronological Index of : Product Discovery & Development

 Current Issue
  • Co-opting expression

    How delivering checkpoint agents via oncolytic viruses could beat combining them

    Preclinical data reported by Transgene at AACR support oncolytic viral delivery of checkpoint agents locally to tumors.

    Published on 4/25/2016
  • Box: Bristol's I/O network

    Survive and advance Bristol's I/O network In 2012, Bristol-Myers Squibb Co. established the International Immuno-Oncology Network (II-ON), a public-private partnership that includes 13 immuno-oncology universities…

    Published on 4/11/2016
  • Table: WHO criteria vs. irRC

    Survive and advance WHO criteria vs. irRC The Cancer Immunotherapy Consortium (CIC) developed the immune-related response criteria (irRC) to overcome shortcomings of WHO response criteria in describing responses …

    Published on 4/11/2016
  • Survive and advance

    Why industry, regulators are thinking about new endpoints for immuno-oncology

    Extended survival provided by immunotherapies means stakeholders are thinking about how to measure benefit for the next generation of immuno-oncology drugs.

    Published on 4/11/2016
  • Portola's mitigating factors

    Why Portola thinks betrixaban could be reviewed for VTE despite Phase III miss

    Despite a Phase III miss, Portola hopes the totality of evidence for betrixaban will support approval of the Factor Xa inhibitor for VTE.

    Published on 4/4/2016
  • Table: Interception deals

    Accelerating the Accelerator Interception deals Janssen Research & Development LLC has done 24 deals and collaborations with partners to support its Disease Interception Accelerator, which the Johnson & Johnson (…

    Published on 3/28/2016
  • Accelerating the Accelerator

    How J&Js plans to intercept COPD, gestational diabetes, HPV-driven cancer

    J&J's Disease Interception Accelerator will mine longitudinal data to uncover and inhibit the triggers of COPD and gestational diabetes.

    Published on 3/28/2016
  • Korea rising

    How the Korean biopharma landscape is evolving

    With the success of Hanmi and an infusion of government money, Korea's biopharma industry is building a virtuous circle for innovation.

    Published on 3/21/2016
  • Box: Baby steps

    Korea rising Baby steps Several Korean biotechs told BioCentury that despite an increase in development of innovator products, the country is lacking in the expertise needed to execute global clinical development …

    Published on 3/21/2016
  • Box: Korea comps

    Korea rising Korea comps B. Christopher Kim, managing partner at Korea-Seoul Life Sciences Fund, told BioCentury the firm did not start out with a Korea focus. The fund closed at W75 billion ($67.5 million) in …

    Published on 3/21/2016
  • Box: Korea opens up

    Korea rising Korea opens up Much like in the U.S. and Europe, established Korean biopharma companies have started to work with local universities and small biotechs to identify and invest in innovative …

    Published on 3/21/2016
  • Figure: R&D growth

    Korea rising R&D growth From 2009 to 2013, R&D spending by the Korean pharmaceutical industry has increased. While absolute spending still pales in comparison to larger countries, Korea's R&D outlays have grown at…

    Published on 3/21/2016
  • Table: Korea funds

    Korea rising Korea funds The South Korean government has launched four funding initiatives totalling $2 billion to help spur R&D for innovative drugs and promote global expansion of the nation's biotech industry. …

    Published on 3/21/2016
  • The missing piece

    How AbbVie's Boehringer deal advances its Humira replacement strategy

    AbbVie's Boehringer deal adds a putative successor to Humira in psoriasis with high efficacy and potential for long dosing intervals.

    Published on 3/14/2016
  • Figure: Covering Humira

    The missing piece Covering Humira AbbVie Inc.’s (NYSE:ABBV) clinical pipeline plus an in-licensed program from Boehringer Ingelheim GmbH appear to cover about 95% of Humira adalimumab’s label based on a back-of-…

    Published on 3/14/2016
  • Getting hip in osteoporosis

    Why romosozumab needs hip data to compete in osteoporosis

    Doctors say Amgen's romosozumab could be competitive with Radius' abaloparatide-SC in osteoporosis if the mAb has some efficacy on hip fractures.

    Published on 3/7/2016
  • Infectious enthusiasm

    How oncolytic viruses are coming of age in cancer immunotherapy combinations

    Checkpoint agents could give oncolytic viruses an efficacy boost as the field learns how to make viruses deliver their own potentiators.

    Published on 2/29/2016
  • Box: Oncolytic duos and Dx

    Infectious enthusiasm Oncolytic duos and Dx Several companies are looking for therapeutic combinations that change how oncolytic viruses interact with cancer cells. At least two companies, Oncolys BioPharma Inc. …

    Published on 2/29/2016
  • Figure: Oncolytic pipeline

    Infectious enthusiasm Oncolytic pipeline At least 19 oncolytic viruses are in clinical development. For products in development for multiple indications, the status of the lead indication is shown. Many viruses …

    Published on 2/29/2016
  • Figure: The BioVex effect

    Infectious enthusiasm The BioVex effect In the last five years, oncolytic virus companies raised $360.2 million via equity offerings, topping the $321.5 million raised in 2000-10. The catalyst of renewed attention…

    Published on 2/29/2016
  • Figure: Two-pronged attack

    Infectious enthusiasm Two-pronged attack Oncolytic viruses can stimulate both direct and indirect killing of cancer cells, as illustrated by Imlygic talimogene laherparepvec (T-Vec) from Amgen Inc. (NASDAQ:AMGN). …

    Published on 2/29/2016
  • Figure: In stereo

    High fidelity In stereo The phosphorothioate linkages that connect nucleotide bases in nucleic acids have a chiral center at the phosphorous molecule. The chirality creates stereoisomers designated as Sp or Rp. …

    Published on 2/15/2016
  • Figure: Making waves

    High fidelity Making waves Wave Life Sciences Ltd. (NASDAQ:WVE) has a pipeline of 23 stereopure nucleic acid programs that span six different disease areas. The biotech plans to have six programs in the clinic by …

    Published on 2/15/2016
  • High fidelity

    How Wave's nucleic acid technology could confer an advantage in Huntington's

    Wave's stereopure nucleic acids could have safety and efficacy advantages over programs in the clinic, starting with its lead HD candidates.

    Published on 2/15/2016
  • Figure: Targeting ST2

    Asthma armament Targeting ST2 In asthma, epithelial tissue damage leads to the release of IL-33, an IL-1 family cytokine. IL-33 binds a heterodimer complex consisting of IL-1 receptor-like 1 (IL1RL1; ST2) and IL-1…

    Published on 2/8/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993